Drug
MK-1293 clinical trials
Also written MK-1293.
A product of Insulin Glargine; its studies count on that page too.
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
3 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses MK-1293 is read from its arms, and is right about nine times in ten.
Testing it · 3
- The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)CompletedPhase 3Merck Sharp & Dohme LLCNCT02059187Written as MK-1293
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)CompletedPhase 1Merck Sharp & Dohme LLCNCT02059174Written as MK-1293
- A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)CompletedPhase 3Merck Sharp & Dohme LLCNCT02059161Written as MK-1293
Codes
What other systems call MK-1293 · ClinicalTrials.gg INT001027
- MeSH (NLM) C000629534MK-1293One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000629534 | MK-1293 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.